• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同胰岛素抵抗相关指标与心脏代谢多重疾病的发病率及进展轨迹的关联:一项来自英国生物银行的前瞻性队列研究

Associations of different insulin resistance-related indices with the incidence and progression trajectory of cardiometabolic multimorbidity: a prospective cohort study from UK biobank.

作者信息

Tian Zhenyu, Yang Lu, Li Yifei, Huang Yueqing, Yang Jianmin, Xue Fei

机构信息

State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China.

Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510120, Guangdong, China.

出版信息

Cardiovasc Diabetol. 2025 Jun 18;24(1):257. doi: 10.1186/s12933-025-02819-0.

DOI:10.1186/s12933-025-02819-0
PMID:40533754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12175334/
Abstract

BACKGROUND

Despite established associations between insulin resistance (IR)-related indices and cardiometabolic diseases (CMDs), most studies are limited to single CMD outcomes. The study aimed to examine the influence of IR-related indices on the incidence, predictive value, and progression trajectory of cardiometabolic multimorbidity (CMM), as well as potential biological mechanisms.

METHODS

This prospective study included 374,274 individuals from the UK Biobank who were free of CMDs at baseline. CMM was defined as the presence of two or more CMDs, including type 2 diabetes (T2D), coronary heart disease (CHD), and stroke. Five indices were developed to assess IR levels: triglyceride-glucose (TyG) index, TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), TyG-waist-height ratio (TyG-WHtR), and triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio. Cox proportional hazards and multi-state models were utilized to examine the associations between IR-related indices and CMM incidence and transition, respectively, with results expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). The predictive utility of these indices was assessed using the net reclassification index (NRI) and integrated discrimination improvement index (IDI). Mediation analyses were conducted to quantify the potential mediating roles of biomarkers.

RESULTS

During a mean follow-up period of 13.7 years, 5048 (1.3%) individuals developed CMM. Elevated baseline IR-related indices were associated with higher risks of incident CMM. The HRs (95% CIs) for each 1-standard deviation increase were as follows: 1.30 (1.26-1.34) for the TyG index, 1.42 (1.39-1.46) for the TyG-BMI, 1.54 (1.49-1.59) for the TyG-WC, 1.52 (1.48-1.57) for the TyG-WHtR, and 1.19 (1.17-1.21) for the TG/HDL-C ratio. Besides, TyG-WHtR and TyG-WC exhibited significantly higher NRI and IDI, indicating superior predictive performance for CMM risk. These indices played critical yet distinct roles in the progression of CMM. For transitions from being free of CMDs to single CMDs, these indices had the strongest impact on T2D (all P < 0.001). Participants initially diagnosed with CHD were more likely to progress to CMM when exposed to higher IR-related indices (all P < 0.001). The effect sizes for TyG-WC and TyG-WHtR were greater than those of other indices across all transitions. Mediation analyses revealed that biomarkers associated with liver function, renal function, and inflammation collectively mediated approximately one-third of the associations of the TyG-WHtR and TyG-WC indices with incident CMM.

CONCLUSIONS

Our findings highlight the critical role of IR-related indices, particularly TyG-WHtR and TyG-WC, in the incidence, progression, and prevention of CMM. The mediation effects of biomarkers indicate the potential for targeted interventions to reduce CMM risk in high-IR individuals.

摘要

背景

尽管胰岛素抵抗(IR)相关指标与心脏代谢疾病(CMD)之间的关联已得到证实,但大多数研究仅限于单一的CMD结局。本研究旨在探讨IR相关指标对心脏代谢多发病(CMM)的发病率、预测价值和进展轨迹的影响,以及潜在的生物学机制。

方法

这项前瞻性研究纳入了英国生物银行的374274名个体,他们在基线时无CMD。CMM被定义为存在两种或更多种CMD,包括2型糖尿病(T2D)、冠心病(CHD)和中风。开发了五个指标来评估IR水平:甘油三酯-葡萄糖(TyG)指数、TyG-体重指数(TyG-BMI)、TyG-腰围(TyG-WC)、TyG-腰高比(TyG-WHtR)和甘油三酯与高密度脂蛋白胆固醇(TG/HDL-C)比值。分别使用Cox比例风险模型和多状态模型来检验IR相关指标与CMM发病率和转变之间的关联,结果以风险比(HR)和95%置信区间(CI)表示。使用净重新分类指数(NRI)和综合判别改善指数(IDI)评估这些指标的预测效用。进行中介分析以量化生物标志物的潜在中介作用。

结果

在平均13.7年的随访期内,5048名(1.3%)个体发生了CMM。基线IR相关指标升高与CMM发病风险较高相关。每增加1个标准差的HR(95%CI)如下:TyG指数为1.30(1.26 - 1.34),TyG-BMI为1.42(1.39 - 1.46),TyG-WC为1.54(1.49 - 1.59),TyG-WHtR为1.52(1.48 - 1.57),TG/HDL-C比值为1.19(1.17 - 1.21)。此外,TyG-WHtR和TyG-WC表现出显著更高的NRI和IDI,表明对CMM风险具有卓越的预测性能。这些指标在CMM的进展中发挥了关键但不同的作用。对于从无CMD到单一CMD的转变,这些指标对T2D的影响最强(所有P < 0.001)。最初被诊断为CHD的参与者在暴露于较高的IR相关指标时更有可能进展为CMM(所有P < 0.001)。在所有转变中,TyG-WC和TyG-WHtR的效应大小大于其他指标。中介分析表明,与肝功能、肾功能和炎症相关的生物标志物共同介导了TyG-WHtR和TyG-WC指数与CMM发病之间约三分之一的关联。

结论

我们的研究结果突出了IR相关指标,特别是TyG-WHtR和TyG-WC,在CMM的发病率、进展和预防中的关键作用。生物标志物的中介作用表明了针对高IR个体进行靶向干预以降低CMM风险的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/494b01b18737/12933_2025_2819_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/03d007f78b9a/12933_2025_2819_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/8d9f3dc35591/12933_2025_2819_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/149040d09315/12933_2025_2819_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/9ea415016125/12933_2025_2819_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/494b01b18737/12933_2025_2819_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/03d007f78b9a/12933_2025_2819_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/8d9f3dc35591/12933_2025_2819_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/149040d09315/12933_2025_2819_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/9ea415016125/12933_2025_2819_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b934/12175334/494b01b18737/12933_2025_2819_Fig5_HTML.jpg

相似文献

1
Associations of different insulin resistance-related indices with the incidence and progression trajectory of cardiometabolic multimorbidity: a prospective cohort study from UK biobank.不同胰岛素抵抗相关指标与心脏代谢多重疾病的发病率及进展轨迹的关联:一项来自英国生物银行的前瞻性队列研究
Cardiovasc Diabetol. 2025 Jun 18;24(1):257. doi: 10.1186/s12933-025-02819-0.
2
Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank.甘油三酯-葡萄糖(TyG)相关指标与代谢功能障碍相关脂肪性肝病患者心血管疾病及死亡率之间的关联:英国生物银行队列研究
Cardiovasc Diabetol. 2025 Jan 13;24(1):12. doi: 10.1186/s12933-024-02572-w.
3
Association between triglyceride-glucose related indices and at-risk NASH in U.S. adults with NAFLD: results from NHANES 2017-2020.美国非酒精性脂肪性肝病(NAFLD)成人患者中甘油三酯-葡萄糖相关指标与高危非酒精性脂肪性肝炎(NASH)的关联:2017 - 2020年美国国家健康与营养检查调查(NHANES)结果
Front Endocrinol (Lausanne). 2025 Jun 4;16:1604991. doi: 10.3389/fendo.2025.1604991. eCollection 2025.
4
Association of different insulin resistance surrogates with all-cause and cardiovascular mortality among the population with cardiometabolic multimorbidity.在患有心脏代谢多种合并症的人群中,不同胰岛素抵抗替代指标与全因死亡率和心血管死亡率的关联。
Cardiovasc Diabetol. 2025 Jan 22;24(1):33. doi: 10.1186/s12933-025-02576-0.
5
The association of obesity and lipid-related indicators with all-cause and cardiovascular mortality risks in patients with diabetes or prediabetes: a cross-sectional study based on machine learning algorithms.肥胖及血脂相关指标与糖尿病或糖尿病前期患者全因死亡和心血管死亡风险的关联:一项基于机器学习算法的横断面研究
Front Endocrinol (Lausanne). 2025 Jun 2;16:1492082. doi: 10.3389/fendo.2025.1492082. eCollection 2025.
6
The triglyceride glucose-waist circumference is the best indicator for screening non-alcoholic fatty liver disease in middle-aged and elderly people.甘油三酯-血糖腰围是中老年人群非酒精性脂肪性肝病筛查的最佳指标。
Nutr Hosp. 2025 Jun 19;43(3):476-484. doi: 10.20960/nh.05367.
7
Triglyceride-glucose-body mass index and the incidence of cardiovascular diseases: a meta-analysis of cohort studies.甘油三酯-葡萄糖-体重指数与心血管疾病发病率:队列研究的荟萃分析
Cardiovasc Diabetol. 2025 Jan 22;24(1):34. doi: 10.1186/s12933-025-02584-0.
8
[Association of triglyceride-glucose index and cardiovascular disease in a community-based Chinese cohort].[基于社区的中国队列中甘油三酯-葡萄糖指数与心血管疾病的关联]
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Jun 18;57(3):430-435. doi: 10.19723/j.issn.1671-167X.2025.03.004.
9
The additive association of cardiometabolic diseases with incident heart failure: a prospective cohort study.心血管代谢疾病与新发心力衰竭的相加关联:一项前瞻性队列研究。
Hellenic J Cardiol. 2025 Jun 18. doi: 10.1016/j.hjc.2025.06.005.
10
Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study.心脏代谢指标与代谢功能障碍相关脂肪性肝病的发病及其向肝纤维化进展之间的关联:一项队列研究
Cardiovasc Diabetol. 2025 Apr 3;24(1):154. doi: 10.1186/s12933-025-02716-6.

本文引用的文献

1
The association between TyG index and cardiovascular mortality is modified by antidiabetic or lipid-lowering agent: a prospective cohort study.TyG指数与心血管死亡率之间的关联因抗糖尿病药物或降脂药物而改变:一项前瞻性队列研究。
Cardiovasc Diabetol. 2025 Feb 7;24(1):65. doi: 10.1186/s12933-025-02620-z.
2
Association of different insulin resistance surrogates with all-cause and cardiovascular mortality among the population with cardiometabolic multimorbidity.在患有心脏代谢多种合并症的人群中,不同胰岛素抵抗替代指标与全因死亡率和心血管死亡率的关联。
Cardiovasc Diabetol. 2025 Jan 22;24(1):33. doi: 10.1186/s12933-025-02576-0.
3
Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank.
甘油三酯-葡萄糖(TyG)相关指标与代谢功能障碍相关脂肪性肝病患者心血管疾病及死亡率之间的关联:英国生物银行队列研究
Cardiovasc Diabetol. 2025 Jan 13;24(1):12. doi: 10.1186/s12933-024-02572-w.
4
Inflammatory markers link triglyceride-glucose index and obesity indicators with adverse cardiovascular events in patients with hypertension: insights from three cohorts.炎症标志物将高血压患者的甘油三酯-葡萄糖指数和肥胖指标与不良心血管事件联系起来:来自三个队列的见解
Cardiovasc Diabetol. 2025 Jan 8;24(1):11. doi: 10.1186/s12933-024-02571-x.
5
Association between major depressive disorder or depressive symptoms and the risk of vascular complications among patients with type 2 diabetes, and the mediating role of metabolic biomarkers: an analysis of the UK Biobank cohort.2型糖尿病患者中重度抑郁症或抑郁症状与血管并发症风险之间的关联以及代谢生物标志物的中介作用:英国生物银行队列分析
EClinicalMedicine. 2024 Dec 6;79:102982. doi: 10.1016/j.eclinm.2024.102982. eCollection 2025 Jan.
6
A Population-Based Study of the Mediating Role of WBC, NEUT and PLT in the Relationship Between Triglyceride-Glucose Index and Urinary Albumin Excretion.一项基于人群的关于白细胞、中性粒细胞和血小板在甘油三酯-葡萄糖指数与尿白蛋白排泄关系中的中介作用的研究。
J Inflamm Res. 2024 Dec 7;17:10613-10626. doi: 10.2147/JIR.S491694. eCollection 2024.
7
Oxidative stress mediates the association between triglyceride-glucose index and risk of cardiovascular and all-cause mortality in metabolic syndrome: evidence from a prospective cohort study.氧化应激介导甘油三酯-葡萄糖指数与代谢综合征患者心血管和全因死亡风险的关联:来自前瞻性队列研究的证据。
Front Endocrinol (Lausanne). 2024 Aug 20;15:1452896. doi: 10.3389/fendo.2024.1452896. eCollection 2024.
8
Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis.甘油三酯-葡萄糖指数的诊断和预后价值:荟萃分析的综合评价。
Cardiovasc Diabetol. 2024 Aug 23;23(1):310. doi: 10.1186/s12933-024-02392-y.
9
Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.甘油三酯葡萄糖相关参数对美国代谢功能障碍相关脂肪性肝病患者全因和心血管死亡率的预后影响。
Cardiovasc Diabetol. 2024 Jun 1;23(1):188. doi: 10.1186/s12933-024-02287-y.
10
Prediabetes Increases the Risk of Frailty in Prefrail Older Adults With Hypertension: Beneficial Effects of Metformin.糖尿病前期增加了高血压衰弱前期老年人衰弱的风险:二甲双胍的有益作用。
Hypertension. 2024 Jul;81(7):1637-1643. doi: 10.1161/HYPERTENSIONAHA.124.23087. Epub 2024 May 16.